A group of Argentine scientists produce in serum, neither in an experimental phase, trying to control the development of Hemolytic Uremic Syndrome (HUS) in humans with a bacterium Escherichia coli.
According to estimates, this can discover the first drug in the world for that purpose. The scientific development, which affects HUS, was presented by Inmunova's laboratory and the Italian Hospital of Buenos Aires, after completing the first phase of clinical studies successfully.
This disease is the major cause of acute renal failure and is responsible for 20 percent of kidney transplants in children and adolescents worldwide.
Ultimately, the World Health Organization states that our country has the highest global incidence of this disease in children under the age of 5, which counts 8.5 per 100 thousand creators.